Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street

341
Comment
Favorite

Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street

The Fly2022-10-27

Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls "a welcome change" after the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

341

Report

Comment

Sunday128
·2022-10-28
Okay
Reply
1
Report
yhl77
·2022-10-28
K
Reply
2
Report
Fold Replies
- Ytyt:
  ok
  2022-10-28
  Reply
  Report
天天有錢賺
·2022-10-28
Ok
Reply
5
Report
Fold Replies
- Sunday128:
  Ok
  2022-10-28
  Reply
  Report
- 天天有錢賺:
  Cool
  2022-10-28
  Reply
  Report
BriBri
·2022-10-28
Nice
Reply
2
Report
投资不是一两天
·2022-10-28
Ok
Reply
4
Report
Fold Replies
- 投资不是一两天:
  ok
  2022-10-28
  Reply
  Report
ML808
·2022-10-28
Interesting
Reply
6
Report
Fold Replies
- El_Nino:
  K
  2022-10-28
  Reply
  Report
- ML808:
  yes
  2022-10-28
  Reply
  Report
Bull888
·2022-10-28
Like
Reply
4
Report
Fold Replies
- Bull888:
  Ok
  2022-10-28
  Reply
  Report
RPGold
·2022-10-28
Ok
Reply
4
Report
Fold Replies
- yhl77:
  k
  2022-10-28
  Reply
  Report
Nichktan
·2022-10-28
Like
Reply
8
Report
Fold Replies
- Angela26:
  ok
  2022-10-28
  Reply
  Report
- DylanT:
  liked
  2022-10-28
  Reply
  Report
seetees
·2022-10-28
Oo
Reply
3
Report
Fold Replies
- MingXuan:
  vv
  2022-10-28
  Reply
  Report
HH9
·2022-10-28
Like
Reply
6
Report
Fold Replies
- Nichktan:
  Ok
  2022-10-28
  Reply
  Report
Alkid
·2022-10-28
Okay
Reply
5
Report
Fold Replies
- Alkid:
  K
  2022-10-28
  Reply
  Report
andrew123
·2022-10-28
Like
Reply
5
Report
Fold Replies
- seetees:
  ok
  2022-10-28
  Reply
  Report
- bluewave:
  Ok
  2022-10-28
  Reply
  Report
Llim
·2022-10-28
Like
Reply
5
Report
Fold Replies
- HH9:
  k
  2022-10-28
  Reply
  Report
ArcherWG
·2022-10-28
Noted
Reply
5
Report
ramius75
·2022-10-28
👌
Reply
2
Report
Dragonroar
·2022-10-28
Wow
Reply
4
Report
Fold Replies
- ArcherWG:
  Yap
  2022-10-28
  Reply
  Report
DricNJicken
·2022-10-28
Ok
Reply
1
Report
cassan
·2022-10-28
Ok
Reply
2
Report
Fold Replies
- Dragonroar:
  wow
  2022-10-28
  Reply
  Report
- cassan:
  Ok
  2022-10-28
  Reply
  Report
Milosoft
·2022-10-28
Ok
Reply
2
Report
Fold Replies
- DricNJicken:
  ok
  2022-10-28
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1182334257?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-10-27 22:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182334257","market":"us","top_or_hot":-1,"title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","media":"The Fly","content":"<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Source Link</a>\n\n</div>\n","source":"lsy1649979459173","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRCY","symbol_name":"Mercury Systems Inc","start_time":0,"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","article_id":"1182334257","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","pubTimestamp":1666879990,"sourceInfo":{"source_id":"lsy1649979459173","name":"The Fly"},"weMediaInfo":null,"summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","collect":0,"end_time":0,"defaultTopTitle":"thefly.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"translate_title":"元平台降级；ServiceNow升级：华尔街的热门电话","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACLX":0.9,"FEAM":0.9,"IDYA":0.9,"MEDP":0.9,"META":0.9,"MRCY":0.9,"NOW":0.9,"PDD":0.9,"RNST":0.9,"ROIV":0.9,"SLAB":0.9,"STX":0.9,"TER":0.9,"TMO":0.9,"VFC":0.9},"content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[{"id":9986133233,"gmtCreate":1666911568422,"gmtModify":1676537827791,"author":{"id":"4099796716910130","authorId":"4099796716910130","name":"Sunday128","avatar":"https://static.tigerbbs.com/f2cc38fb8b7ce0ae876f3a7b6154dfe0","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9986133233","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9986139522,"gmtCreate":1666911401867,"gmtModify":1676537827765,"author":{"id":"3578210330936790","authorId":"3578210330936790","name":"yhl77","avatar":"https://static.tigerbbs.com/e3f5d104b4f554fe3544bdd3abd635ae","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9986139522","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104542607,"gmtCreate":1666913588154,"gmtModify":1666913591637,"authorId":4094269572113460,"author":{"id":4094269572113460,"authorId":4094269572113460,"name":"Ytyt","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986139522,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":9986197768,"gmtCreate":1666911220455,"gmtModify":1676537827708,"author":{"id":"3569157961325264","authorId":"3569157961325264","name":"天天有錢賺","avatar":"https://static.tigerbbs.com/a87d6821c87a3f5345fd3b39e87a3710","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9986197768","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104542017,"gmtCreate":1666911579418,"gmtModify":1666911582800,"authorId":4099796716910130,"author":{"id":4099796716910130,"authorId":4099796716910130,"name":"Sunday128","avatar":"https://static.tigerbbs.com/f2cc38fb8b7ce0ae876f3a7b6154dfe0","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.05","exceedPercentage":"60.28%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986197768,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"},{"id":104541941,"gmtCreate":1666911227648,"gmtModify":1666911230959,"authorId":3569157961325264,"author":{"id":3569157961325264,"authorId":3569157961325264,"name":"天天有錢賺","avatar":"https://static.tigerbbs.com/a87d6821c87a3f5345fd3b39e87a3710","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986197768,"type":1,"supId":0,"prevId":0,"content":"Cool","text":"Cool","html":"Cool"}],"langContent":"EN"},{"id":9986194195,"gmtCreate":1666911101317,"gmtModify":1676537827660,"author":{"id":"3581814892991688","authorId":"3581814892991688","name":"BriBri","avatar":"https://static.tigerbbs.com/a491a55c22a61b336ee95f092d522622","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9986194195","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9986195561,"gmtCreate":1666911071954,"gmtModify":1676537827643,"author":{"id":"3576138559006730","authorId":"3576138559006730","name":"投资不是一两天","avatar":"https://static.tigerbbs.com/36e77b5b6d744959b49fda03e290c69b","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9986195561","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104541915,"gmtCreate":1666911076620,"gmtModify":1666911080065,"authorId":3576138559006730,"author":{"id":3576138559006730,"authorId":3576138559006730,"name":"投资不是一两天","avatar":"https://static.tigerbbs.com/36e77b5b6d744959b49fda03e290c69b","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986195561,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":9986195614,"gmtCreate":1666911051138,"gmtModify":1676537827642,"author":{"id":"3582359360248748","authorId":"3582359360248748","name":"ML808","avatar":"https://static.tigerbbs.com/f601c68849ffbac8b7679f40f1471368","vip":1,"hat":"https://static.tigerbbs.com/7b75ce0c34afff716602792a5d0929dd","crmLevel":4,"crmLevelSwitch":0},"htmlText":"Interesting&nbsp;","listText":"Interesting&nbsp;","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9986195614","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104541926,"gmtCreate":1666911161729,"gmtModify":1666911165115,"authorId":3579591519090572,"author":{"id":3579591519090572,"authorId":3579591519090572,"name":"El_Nino","avatar":"https://static.tigerbbs.com/6b1b731af69caf76640812930188d9d2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986195614,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">K</span>","text":"<span class=\"s1\">K</span>","html":"<span class=\"s1\">K</span>"},{"id":104541911,"gmtCreate":1666911059059,"gmtModify":1666911063006,"authorId":3582359360248748,"author":{"id":3582359360248748,"authorId":3582359360248748,"name":"ML808","avatar":"https://static.tigerbbs.com/f601c68849ffbac8b7679f40f1471368","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986195614,"type":1,"supId":0,"prevId":0,"content":"<u>yes</u>","text":"<u>yes</u>","html":"<u>yes</u>"}],"langContent":"EN"},{"id":9986196559,"gmtCreate":1666910899771,"gmtModify":1676537827584,"author":{"id":"3579315453167562","authorId":"3579315453167562","name":"Bull888","avatar":"https://static.tigerbbs.com/ed0dd70f3590d98b041e28374466e9d3","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9986196559","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104541883,"gmtCreate":1666910945031,"gmtModify":1666910948756,"authorId":3579315453167562,"author":{"id":3579315453167562,"authorId":3579315453167562,"name":"Bull888","avatar":"https://static.tigerbbs.com/ed0dd70f3590d98b041e28374466e9d3","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986196559,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"}],"langContent":"EN"},{"id":9986198272,"gmtCreate":1666910769896,"gmtModify":1676537827556,"author":{"id":"4103929380960260","authorId":"4103929380960260","name":"RPGold","avatar":"https://static.itradeup.com/news/7b411b17585df3db54c94d5ebe3e8ce3","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9986198272","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104541973,"gmtCreate":1666911396595,"gmtModify":1666911399810,"authorId":3578210330936790,"author":{"id":3578210330936790,"authorId":3578210330936790,"name":"yhl77","avatar":"https://static.tigerbbs.com/e3f5d104b4f554fe3544bdd3abd635ae","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986198272,"type":1,"supId":0,"prevId":0,"content":"<u>k</u>","text":"<u>k</u>","html":"<u>k</u>"}],"langContent":"EN"},{"id":9986198015,"gmtCreate":1666910697437,"gmtModify":1676537827536,"author":{"id":"3567067978989911","authorId":"3567067978989911","name":"Nichktan","avatar":"https://static.tigerbbs.com/73a93daf14236dfaeabaf3ea0b82fe4d","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9986198015","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104541901,"gmtCreate":1666911025660,"gmtModify":1666911028955,"authorId":3575785954938833,"author":{"id":3575785954938833,"authorId":3575785954938833,"name":"Angela26","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986198015,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":104541874,"gmtCreate":1666910874147,"gmtModify":1666910877850,"authorId":3582541483650512,"author":{"id":3582541483650512,"authorId":3582541483650512,"name":"DylanT","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986198015,"type":1,"supId":0,"prevId":0,"content":"<u>liked</u>","text":"<u>liked</u>","html":"<u>liked</u>"}],"langContent":"EN"},{"id":9986191830,"gmtCreate":1666910595021,"gmtModify":1676537827518,"author":{"id":"3562561688574892","authorId":"3562561688574892","name":"seetees","avatar":"https://static.tigerbbs.com/35829985f82fe3d891b427ca34c3e0b8","vip":1,"crmLevel":2,"crmLevelSwitch":1},"htmlText":"Oo","listText":"Oo","text":"Oo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9986191830","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104541898,"gmtCreate":1666911008936,"gmtModify":1666911012474,"authorId":3568776369893575,"author":{"id":3568776369893575,"authorId":3568776369893575,"name":"MingXuan","avatar":"https://static.tigerbbs.com/b6843a33a5048452e1f1380ec02671e9","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.09%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986191830,"type":1,"supId":0,"prevId":0,"content":"<u>vv</u>","text":"<u>vv</u>","html":"<u>vv</u>"}],"langContent":"EN"},{"id":9986199749,"gmtCreate":1666910352282,"gmtModify":1676537827478,"author":{"id":"3583021527520221","authorId":"3583021527520221","name":"HH9","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9986199749","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104541853,"gmtCreate":1666910733664,"gmtModify":1666910737489,"authorId":3567067978989911,"author":{"id":3567067978989911,"authorId":3567067978989911,"name":"Nichktan","avatar":"https://static.tigerbbs.com/73a93daf14236dfaeabaf3ea0b82fe4d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986199749,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"}],"langContent":"EN"},{"id":9986199462,"gmtCreate":1666910351257,"gmtModify":1676537827471,"author":{"id":"3574044380631135","authorId":"3574044380631135","name":"Alkid","avatar":"https://static.tigerbbs.com/d584ca72b32575d58fab92034b2973bc","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9986199462","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104541780,"gmtCreate":1666910361062,"gmtModify":1666910364824,"authorId":3574044380631135,"author":{"id":3574044380631135,"authorId":3574044380631135,"name":"Alkid","avatar":"https://static.tigerbbs.com/d584ca72b32575d58fab92034b2973bc","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.86%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986199462,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">K</span>","text":"<span class=\"s1\">K</span>","html":"<span class=\"s1\">K</span>"}],"langContent":"EN"},{"id":9986199897,"gmtCreate":1666910332219,"gmtModify":1676537827461,"author":{"id":"3576260758860416","authorId":"3576260758860416","name":"andrew123","avatar":"https://community-static.tradeup.com/news/f3e049e64de259e717c6e652c0aca653","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":5,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9986199897","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104541830,"gmtCreate":1666910601556,"gmtModify":1666910605231,"authorId":3562561688574892,"author":{"id":3562561688574892,"authorId":3562561688574892,"name":"seetees","avatar":"https://static.tigerbbs.com/35829985f82fe3d891b427ca34c3e0b8","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986199897,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":104541813,"gmtCreate":1666910477980,"gmtModify":1666910481417,"authorId":3578259981610721,"author":{"id":3578259981610721,"authorId":3578259981610721,"name":"bluewave","avatar":"https://static.tigerbbs.com/8e71f1454119ff144295c97018b0ca47","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.18%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986199897,"type":1,"supId":0,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"}],"langContent":"EN"},{"id":9986190871,"gmtCreate":1666910188993,"gmtModify":1676537827433,"author":{"id":"4105239963331670","authorId":"4105239963331670","name":"Llim","avatar":"https://community-static.tradeup.com/news/ebdd6aa492c9d80d8a2c1a18334bff87","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9986190871","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104541782,"gmtCreate":1666910362573,"gmtModify":1666910365900,"authorId":3583021527520221,"author":{"id":3583021527520221,"authorId":3583021527520221,"name":"HH9","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986190871,"type":1,"supId":0,"prevId":0,"content":"<u>k</u>","text":"<u>k</u>","html":"<u>k</u>"}],"langContent":"EN"},{"id":9986107050,"gmtCreate":1666910032671,"gmtModify":1676537827383,"author":{"id":"3581837121803380","authorId":"3581837121803380","name":"ArcherWG","avatar":"https://community-static.tradeup.com/news/38e40c44fababa6849ceb15dfe8931a3","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Noted","listText":"Noted","text":"Noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9986107050","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9986104977,"gmtCreate":1666909947399,"gmtModify":1676537827229,"author":{"id":"3586470645934044","authorId":"3586470645934044","name":"ramius75","avatar":"https://community-static.tradeup.com/news/c4c299991e47de2cfc27ff1e679cc5ee","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":5,"crmLevelSwitch":1},"htmlText":"👌","listText":"👌","text":"👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9986104977","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9986105473,"gmtCreate":1666909935793,"gmtModify":1676537827220,"author":{"id":"3586969379790251","authorId":"3586969379790251","name":"Dragonroar","avatar":"https://static.tigerbbs.com/c85f59035023e669e7f4f44f503edbbe","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9986105473","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104541734,"gmtCreate":1666910027503,"gmtModify":1666910030805,"authorId":3581837121803380,"author":{"id":3581837121803380,"authorId":3581837121803380,"name":"ArcherWG","avatar":"https://community-static.tradeup.com/news/38e40c44fababa6849ceb15dfe8931a3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986105473,"type":1,"supId":0,"prevId":0,"content":"<u>Yap</u>","text":"<u>Yap</u>","html":"<u>Yap</u>"}],"langContent":"EN"},{"id":9986106051,"gmtCreate":1666909615773,"gmtModify":1676537827148,"author":{"id":"3582023360578743","authorId":"3582023360578743","name":"DricNJicken","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9986106051","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9986108128,"gmtCreate":1666909515264,"gmtModify":1676537827120,"author":{"id":"3562891229203554","authorId":"3562891229203554","name":"cassan","avatar":"https://static.tigerbbs.com/2f12a58ed338611b5e581e7f21ac579b","vip":1,"crmLevel":5,"crmLevelSwitch":1},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9986108128","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104541713,"gmtCreate":1666909941105,"gmtModify":1666909945042,"authorId":3586969379790251,"author":{"id":3586969379790251,"authorId":3586969379790251,"name":"Dragonroar","avatar":"https://static.tigerbbs.com/c85f59035023e669e7f4f44f503edbbe","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986108128,"type":1,"supId":0,"prevId":0,"content":"<u>wow</u>","text":"<u>wow</u>","html":"<u>wow</u>"},{"id":104541517,"gmtCreate":1666909522348,"gmtModify":1666909525894,"authorId":3562891229203554,"author":{"id":3562891229203554,"authorId":3562891229203554,"name":"cassan","avatar":"https://static.tigerbbs.com/2f12a58ed338611b5e581e7f21ac579b","vip":1,"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986108128,"type":1,"supId":0,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"}],"langContent":"EN"},{"id":9986103134,"gmtCreate":1666909380728,"gmtModify":1676537827073,"author":{"id":"3579596231052016","authorId":"3579596231052016","name":"Milosoft","avatar":"https://static.tigerbbs.com/6ae762f5bbae5517a60fac2ee425481c","vip":1,"crmLevel":5,"crmLevelSwitch":1},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9986103134","repostId":1182334257,"repostType":4,"repost":{"id":"1182334257","pubTimestamp":1666879990,"share":"https://www.laohu8.com/m/news/1182334257?lang=&edition=full","pubTime":"2022-10-27 22:13","market":"us","language":"en","title":"Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1182334257","media":"The Fly","summary":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from M","content":"<html><head></head><body><p><b>Top 5 Upgrades:</b></p><ul><li>MoffettNathanson analyst Sterling Auty upgraded <b>ServiceNow</b> (NOW) to Outperform from Market Perform with a $549 price target following a report he calls &#34;a welcome change&#34; after the disappointing results from Microsoft (MSFT).</li><li>Craig-Hallum analyst Christian Schwab upgraded <b>Teradyne</b> (TER) to Buy from Hold with a $120 price target following the company&#39;s better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.</li><li>Barclays analyst Jiong Shao upgraded <b>Pinduoduo</b> (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo &#34;provides quite limited disclosures,&#34; its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.</li><li>Raymond James analyst Michael Rose upgraded <b>Renasant</b> (RNST) to Outperform from Market Perform with a $41 price target. Renasant&#39;s third quarter results exceeded expectations on a core basis, and Rose&#39;s now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.</li><li>UBS analyst John Sourbeer upgraded <b>Medpace</b> (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company&#39;s third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.</li></ul><p><b>Top 5 Downgrades:</b></p><ul><li>Morgan Stanley analyst Brian Nowak downgraded <b>Meta Platforms</b> (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta&#39;s &#34;latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.&#34; Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.</li><li>UBS analyst Timothy Arcuri downgraded <b>Seagate</b> (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates &#34;too much potential risk,&#34; the analyst tells investors in a research note.</li><li>JPMorgan analyst Matthew Boss downgraded <b>VF Corp.</b> (VFC) to Underweight from Neutral with a $29 price target. The company reported &#34;mixed&#34; second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.</li><li>Benchmark analyst Robert Wasserman downgraded <b>Thermo Fisher</b> (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.</li><li>Needham analyst Rajvindra Gill downgraded <b>Silicon Labs</b> (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.</li></ul><p><b>Top 5 Initiations:</b></p><ul><li>Raymond James analyst Brian Gesuale initiated coverage of <b>Mercury Systems</b> (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.</li><li>Citi analyst Yigal Nochomovitz initiated coverage of <b>Ideaya Biosciences</b> (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a &#34;powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,&#34; Nochomovitz tells investors in a research note.</li><li>Needham analyst Gil Blum initiated coverage of <b>Arcellx</b> (ACLX) with a Buy rating and $31 price target. Arcellx&#39;s lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.</li><li>B. Riley analyst Matthew Key initiated coverage of <b>5E Advanced Metals</b> (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.</li><li>JPMorgan analyst Brian Cheng initiated coverage of <b>Roivant Sciences</b> (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant&#39;s Vtama sales in plaque psoriasis and potentially in atopic dermatitis.</li></ul></body></html>","source":"lsy1649979459173","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeta Platforms Downgrades; ServiceNow Upgrade: Top Calls on Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-27 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations><strong>The Fly</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the ...</p>\n\n<a href=\"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRCY":"Mercury Systems Inc","MEDP":"Medpace Holdings Inc.","ROIV":"Roivant Sciences Ltd.","META":"Meta Platforms","RNST":"Renasant Corporation","IDYA":"IDEAYA Biosciences","SLAB":"芯科实验室","PDD":"拼多多","VFC":"威富集团","FEAM":"5E Advanced Materials Inc","STX":"希捷科技","TMO":"赛默飞世尔","ACLX":"ARCELLX, INC.","NOW":"ServiceNow","TER":"泰瑞达"},"source_url":"https://thefly.com/landingPageNews.php?id=3604229&headline=NOW;MSFT;TER;PDD;RNST;MEDP;META;STX;VFC;TMO;SLAB;MRCY;IDYA;ACLX;FEAM;ROIV-Street-Wrap-Todays-Top--Upgrades-Downgrades-Initiations","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182334257","content_text":"Top 5 Upgrades:MoffettNathanson analyst Sterling Auty upgraded ServiceNow (NOW) to Outperform from Market Perform with a $549 price target following a report he calls \"a welcome change\" after the disappointing results from Microsoft (MSFT).Craig-Hallum analyst Christian Schwab upgraded Teradyne (TER) to Buy from Hold with a $120 price target following the company's better results. The analyst notes the company saw semi test demand hold up better than originally feared and outperformed on its supply chain during the quarter.Barclays analyst Jiong Shao upgraded Pinduoduo (PDD) to Overweight from Equal Weight with a price target of $70, up from $66. Despite the fact that Pinduoduo \"provides quite limited disclosures,\" its recent progress in adding more brands to its platform in China is impressive, Shao told investors in a research note.Raymond James analyst Michael Rose upgraded Renasant (RNST) to Outperform from Market Perform with a $41 price target. Renasant's third quarter results exceeded expectations on a core basis, and Rose's now positive bias fits the view that the company/stock reflects its conservative lending culture and expectations for better than peer through the cycle loss content, strong low-cost core deposit base that should result in lower costs/betas than most peers/the industry, solid capital position, and strong loan loss reserves.UBS analyst John Sourbeer upgraded Medpace (MEDP) to Neutral from Sell with a price target of $238, up from $142. The analyst cites the company's third quarter earnings beat as it delivered upside against his negative outlook in spite of the outsized biotech exposure and the overall biopharma funding pressures.Top 5 Downgrades:Morgan Stanley analyst Brian Nowak downgraded Meta Platforms (META) to Equal Weight from Overweight with a price target of $105, down from $205, following quarterly results. The analyst Meta's \"latest results and forward capex guidance are thesis changing and likely to weigh on the shares for some period.\" Cowen and KeyBanc also downgraded Meta Platforms to Neutral-equivalent ratings.UBS analyst Timothy Arcuri downgraded Seagate (STX) to Neutral from Buy with a price target of $55, down from $85. The charge by the U.S. Commerce Department that the company shipped product to customers on the Entity List creates \"too much potential risk,\" the analyst tells investors in a research note.JPMorgan analyst Matthew Boss downgraded VF Corp. (VFC) to Underweight from Neutral with a $29 price target. The company reported \"mixed\" second quarter results and a second half of the year guidance cut, Boss tells investors in a research note.Benchmark analyst Robert Wasserman downgraded Thermo Fisher (TMO) to Hold from Buy with no price target. The analyst notes the company reported better-than-expected earnings for Q3, but says concerns over lower sales in Europe due to foreign exchange and other factors puts a damper on 2023 forecasts.Needham analyst Rajvindra Gill downgraded Silicon Labs (SLAB) to Hold from Buy without a price target on slowing consumer demand concerns.Top 5 Initiations:Raymond James analyst Brian Gesuale initiated coverage of Mercury Systems (MRCY) with an Outperform rating and $55 price target. Mercury is the leading platform-agnostic provider of trusted computing and processing solutions used in national defense/aviation systems, Gesuale tells investors in a research note.Citi analyst Yigal Nochomovitz initiated coverage of Ideaya Biosciences (IDYA) with a Buy rating and $26 price target. Ideaya is a clinical-stage oncology company focused on synthetic lethality, a \"powerful therapeutic concept garnering significant attention from biotech/pharma in recent years,\" Nochomovitz tells investors in a research note.Needham analyst Gil Blum initiated coverage of Arcellx (ACLX) with a Buy rating and $31 price target. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for treatment of relapsed or refractory multiple myeloma, Blum tells investors in a research note.B. Riley analyst Matthew Key initiated coverage of 5E Advanced Metals (FEAM) with a Buy rating and $20 price target, which implies roughly 75% potential upside.JPMorgan analyst Brian Cheng initiated coverage of Roivant Sciences (ROIV) with an Overweight rating and $7 price target. The analyst believes the company is attractively positioned with a solid support to valuation from Dermavant's Vtama sales in plaque psoriasis and potentially in atopic dermatitis.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":104541564,"gmtCreate":1666909620434,"gmtModify":1666909623777,"authorId":3582023360578743,"author":{"id":3582023360578743,"authorId":3582023360578743,"name":"DricNJicken","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9986103134,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":341,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}